DelveInsight
DelveInsight
Hemophilia B - Epidemiology Forecast to 2030

  • Published Date : Jan 2021

  • Pages : 100

  • Delivery Time : 24 Hours

  • Region : United States, EU5, Japan

Hemophilia B Epidemiology Forecast Insight

DelveInsight’s ‘Hemophilia B - Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Hemophilia B epidemiology in the 7MM, i.e., the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2018–2030

Hemophilia B Understanding

Hemophilia is defined as an inherited bleeding disorder in which the blood does not clot properly. This can lead to spontaneous bleeding as well as bleeding following injuries or surgery. It is caused by a gene defect that decides how factors VIII, IX, or XI are produced by the body. One of the Hemophilia type is Hemophilia B, also called factor IX (FIX) deficiency or Christmas disease, is a genetic disorder caused by missing or defective factor IX, a clotting protein. Although it is passed down from parents to children, about one-third of cases are caused by a spontaneous mutation, a change in a gene. Clotting factors are specialized proteins needed for blood clotting, the process by which blood seals a wound to stop bleeding and promote healing. The two main symptoms are bleeding for longer than normal, and bruising easily. With this disease, even a small bump to the head can be serious. Diagnosis of hemophilia B is made by investigating the patient’s personal history of bleeding, the patient’s family history of bleeding and inheritance, and laboratory testing. Several different specialized tests are necessary to confirm a diagnosis of hemophilia B. In order to determine if an individual has hemophilia B, specialized blood coagulation tests are used to measure how long it takes the blood to clot. The initial test is the activated partial thromboplastin time (aPTT). If the results of the aPTT test are abnormal, more specific blood tests must be used to determine if the cause of the abnormal aPTT is due to a deficiency of factor IX/hemophilia B, factor VIII/hemophilia A or another clotting factor. A specific factor assay also determines the severity level of the factor deficiency. Individuals with mild hemophilia have factor IX levels between 5 and 40% of normal; those with moderate hemophilia have factor levels from 1 to 5% of normal; and individuals with severe hemophilia have factor levels <1% of normal.

Epidemiology Perspective by DelveInsight

The Hemophilia B epidemiology division provides the insights about historical and current Hemophilia B patient pool and forecasted trend for each seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

In 2020, the overall prevalent cases of Hemophilia B accessed to be around 10,739 in the 7MM, which are expected to grow during the study period, i.e., 2018–2030.

The disease epidemiology covered in the report provides historical as well as forecasted Hemophilia B epidemiology [segmented as Total diagnosed Prevalent Pool of Hemophilia B, Severity-specific Prevalent Pool of Hemophilia B, Prevalent population of Hemophilia B with or without Inhibitors and Treated Prevalent Population of Hemophilia B] in the 7MM, covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom), and Japan from 2020 to 2030.

Country Wise- Hemophilia B Epidemiology

  • In the United States, the total number of prevalent cases of Hemophilia B was 4,134 cases in the year 2020 which are expected to grow during the study period, i.e., 2018–2030.
  • In the year 2020, the total prevalent cases of Hemophilia B were 5,408 in EU-5, which are expected to grow during the study period, i.e., 2018–2030.
  • In Japan, the total number of prevalent cases of Hemophilia B was 1,198 in the year 2020 which are expected to grow during the study period, i.e., 2018–2030.
  • Moderate and severe accounts for ~75% of the Hemophilia B patient pool. In the 7MM, there were around 8,054 moderate and severe Hemophilia B cases in 2020.
  • In the 7MM, approximately 5% of Hemophilia B cases develop inhibitors, i.e., 537 patients with inhibitors in 2020. In addition to this, 95% of the Hemophilia B cases were observed without inhibitors. The number of cases for both categories will increase during the study period.

Scope of the Report

  • The Hemophilia B report covers a detailed overview explaining its causes, symptoms, and pathophysiology, diagnosis, and treatment patterns.
  • The Hemophilia B Report and Model provide an overview of the risk factors and global trends of Hemophilia B in the seven major markets (7MM: United States, Germany, France, Italy, Spain, and the United Kingdom, and Japan)
  • The report provides insight about the historical and forecasted patient pool of Hemophilia B in seven major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.
  • The report assesses the disease risk and burden and highlights the unmet needs of Hemophilia B.
  • The report provides the segmentation of the Hemophilia B epidemiology by diagnosed prevalent cases in the 7MM.
  • The report provides the segmentation of the Hemophilia B epidemiology by severity-specific cases of Hemophilia B in the 7MM.
  • The report provides the segmentation of the Hemophilia B epidemiology by with inhibitor and without inhibitor-specific cases B in the 7MM.
  • The report provides the segmentation of the Hemophilia B epidemiology by treated cases of in the 7MM.

Report Highlights

  • 10-Year Forecast of Hemophilia B epidemiology
  • 7MM Coverage
  • Total diagnosed Prevalent Pool of Hemophilia B
  • Severity-specific Prevalent Pool of Hemophilia B
  • Prevalent population of Hemophilia B with or without Inhibitors
  • Treated Prevalent Population of Hemophilia B

KOL-Views

We interview, KOL’s and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the over Hemophilia B scenario of the indications.

Key Questions Answered

  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Hemophilia B?
  • What are the key findings pertaining to the Hemophilia B epidemiology across the 7MM and which country will have the highest number of patients during the study period (2018–2030)?
  • What would be the total number of patients of Hemophilia B across the 7MM during the study period (2018–2030)?
  • Among the EU5 countries, which country will have the highest number of patients during the study period (2018–2030)?
  • At what CAGR the patient population is expected to grow in the 7MM during the study period (2018–2030)?
  • What are the various recent and upcoming events which are expected to improve the diagnosis of Hemophilia B?

Reasons to buy

The Hemophilia B Epidemiology report will allow the user to -

  • Develop business strategies by understanding the trends shaping and driving the global Hemophilia B market
  • Quantify patient populations in the global Hemophilia B market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and gender that present the best opportunities for Hemophilia B therapeutics in each of the markets covered
  • Understand the magnitude of Hemophilia B population by its severity
  • The Hemophilia B epidemiology report and model were written and developed by Masters and PhD level epidemiologists
  • The Hemophilia B Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 10-year forecast period using reputable sources

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

1. Key Insights

2. Executive Summary of Hemophilia B

3. Epidemiology an d Market Methodology

4. Hemophilia B: Disease Background and Overview

4.1. Classification of Hemophilia

4.2. Sign and Symptoms of Hemophilia B

4.3. The severity of Hemophilia B

4.4. Risk factors and causes of Hemophilia B

4.5. Pathophysiology

4.6. Genetics of Hemophilia B

4.7. Hemophilia and Inhibitors

4.8. Diagnosis

4.9. Diagnostic Algorithm

4.10. Differential diagnosis of Hemophilia B

4.11. Diagnostic Guidelines for Emergency Department Management of Individuals with Hemophilia and Other Bleeding Disorders

4.12. World Federation of Hemophilia (WFH) Guidelines for Diagnosis of Hemophilia

5. Epidemiology and Patient Population

5.1. Epidemiology Key Findings

5.2. Assumptions and Rationale: 7MM

5.3. Epidemiology Scenario: 7MM

5.3.1. Total Diagnosed Prevalent Population of Hemophilia B in the 7MM

5.3.2. Severity- Specific Prevalent Population of Hemophilia B in the 7MM

5.3.3. Prevalent population of Hemophilia B with or without Inhibitors the 7MM

5.3.4. Treated Prevalent Population of Hemophilia B in the 7MM

5.4. United States Epidemiology

5.4.1. Total Diagnosed Prevalent Population of Hemophilia B in the United States

5.4.2. Severity- Specific Prevalent Population of Hemophilia B in the United States

5.4.3. Prevalent population of Hemophilia B with Inhibitors and Without Inhibitors in the United States

5.4.4. Treated Prevalent Population of Hemophilia B in the United States

5.5. EU-5 Country-wise Epidemiology

5.5.1. Germany Epidemiology

5.5.1.1. Total Diagnosed Prevalent Population of Hemophilia B in Germany

5.5.1.2. Severity- Specific Prevalent Population of Hemophilia B in Germany

5.5.1.3. Prevalent population of Hemophilia B with or without Inhibitors in Germany

5.5.1.4. Treated Prevalent Population of Hemophilia B in Germany

5.5.2. France Epidemiology

5.5.2.1. Total Diagnosed Prevalent Population of Hemophilia B in France

5.5.2.2. Severity- Specific Prevalent Population of Hemophilia B in France

5.5.2.3. Prevalent population of Hemophilia B with or without Inhibitors in France

5.5.2.4. Treated Prevalent Population of Hemophilia B in France

5.5.3. Italy Epidemiology

5.5.3.1. Total Diagnosed Prevalent Population of Hemophilia B in Italy

5.5.3.2. Severity-Specific Prevalent Population of Hemophilia B in Italy

5.5.3.3. Prevalent population of Hemophilia B with or without Inhibitors in Italy

5.5.3.4. Treated Prevalent Population of Hemophilia B in Italy

5.5.4. Spain Epidemiology

5.5.4.1. Total Diagnosed Prevalent Population of Hemophilia B in Spain

5.5.4.2. Severity- Specific Prevalent Population of Hemophilia B in Spain

5.5.4.3. Prevalent population of Hemophilia B with or without Inhibitors in Spain

5.5.4.4. Treated Prevalent Population of Hemophilia B in Spain

5.5.5. United Kingdom Epidemiology

5.5.5.1. Total Diagnosed Prevalent Population of Hemophilia B in the United Kingdom

5.5.5.2. Severity-Specific Prevalent Population of Hemophilia B in the United Kingdom

5.5.5.3. Prevalent population of Hemophilia B with or without Inhibitors in the United Kingdom

5.5.5.4. Treated Prevalent Population of Hemophilia B in the United Kingdom

5.6. Japan Epidemiology

5.6.1. Total Diagnosed Prevalent Population of Hemophilia B in Japan

5.6.2. Severity- Specific Prevalent Population of Hemophilia B in Japan

5.6.3. Prevalence of Hemophilia B with Inhibitors and Without Inhibitors in Japan

5.6.4. Treated Prevalent Population of Hemophilia B in Japan

6. Appendix

6.1. Bibliography

6.2. Report Methodology

7. DelveInsight Capabilities

8. Disclaimer

9. About DelveInsight

List of Tables:

  • Table 1: Summary of Hemophilia B; Epidemiology, and Key Events (2018–2030)
  • Table 2: Clotting Factor Tests
  • Table 3: Differential diagnosis of hemophilia B
  • Table 4: Total Diagnosed Prevalence of Hemophilia B in the 7MM (2018–2030)
  • Table 5: Severity- Specific Prevalent Population of Hemophilia B in the 7MM (2018–2030)
  • Table 6: Prevalent population of Hemophilia B with or without Inhibitors the 7MM (2018–2030)
  • Table 7: Treated Prevalent Population of Hemophilia B in the 7MM (2018–2030)
  • Table 8: Total Diagnosed Prevalent Population of Hemophilia B in the United States (2018–2030)
  • Table 9: Severity- Specific Prevalent Population of Hemophilia B in the United States (2018–2030)
  • Table 10: Prevalent population of Hemophilia B with Inhibitors and Without Inhibitors in the United States (2018–2030)
  • Table 11: Treated Prevalent Population of Hemophilia B in the United States (2018–2030)
  • Table 12: Total Diagnosed Prevalent Population of Hemophilia B in Germany (2018–2030)
  • Table 13: Severity- Specific Prevalent Population of Hemophilia B in Germany (2018–2030)
  • Table 14: Prevalent population of Hemophilia B with or without Inhibitors in Germany (2018–2030)
  • Table 15: Treated Prevalent Population of Hemophilia B in Germany (2018–2030)
  • Table 16: Total Diagnosed Prevalent Population of Hemophilia B in France (2018–2030)
  • Table 17: Severity- Specific Prevalent Population of Hemophilia B in France (2018–2030)
  • Table 18: Prevalent population of Hemophilia B with or without Inhibitors in France (2018–2030)
  • Table 19: Treated Prevalent Population of Hemophilia B in France (2018–2030)
  • Table 20: Total Diagnosed Prevalent Population of Hemophilia B in Italy (2018–2030)
  • Table 21: Severity-Specific Diagnosed Prevalence of Hemophilia B in Italy (2018–2030)
  • Table 22: Prevalent population of Hemophilia B with or without Inhibitors in Italy (2018–2030)
  • Table 23: Treated Prevalent Population of Hemophilia B in Italy (2018–2030)
  • Table 24: Total Diagnosed Prevalent Population of Hemophilia B in Spain (2018–2030)
  • Table 25: Severity-Specific Prevalent Population of Hemophilia B in Spain (2018–2030)
  • Table 26: Prevalent population of Hemophilia B with or without Inhibitors in Spain (2018–2030)
  • Table 27: Treated Prevalent Population of Hemophilia B in Spain (2018–2030)
  • Table 28: Total Diagnosed Prevalent Population of Hemophilia B in the United Kingdom (2018–2030)
  • Table 29: Severity-Specific Prevalent Population of Hemophilia B in the United Kingdom (2018–2030)
  • Table 30: Prevalent population of Hemophilia B with or without Inhibitors in the United Kingdom (2018–2030)
  • Table 31: Treated Prevalent Population of Hemophilia B in the United Kingdom (2018–2030)
  • Table 32: Total Diagnosed Prevalent Population of Hemophilia B in Japan (2018–2030)
  • Table 33: Severity- Specific Prevalent Population of Hemophilia B in Japan (2018–2030)
  • Table 34: Prevalence of Hemophilia B with Inhibitors and Without Inhibitors in Japan (2018–2030)
  • Table 35: Treated Prevalent Population of Hemophilia B in Japan (2018–2030)

List of Figures:

  • Figure 1: Hemophilia B
  • Figure 2: Types of Hemophilia
  • Figure 3: Signs and Symptoms of Hemophilia B
  • Figure 4: Severity of the disease on the basis of clotting factors
  • Figure 5: Inheritance Pattern for Hemophilia B
  • Figure 6: Severity of the disease on the basis of clotting factors
  • Figure 7: Vitamin K-dependent carboxylation
  • Figure 8: Inheritance pattern if the mother is the carrier of Hemophilia B gene
  • Figure 9: Inheritance pattern if the father has Hemophilia B
  • Figure 10: Inheritance pattern if the mother is a carrier and the father has Hemophilia B
  • Figure 11: Inhibitors and Hemophilia B
  • Figure 12: Diagnostic Algorithm
  • Figure 13: Total Diagnosed Prevalent Population of Hemophilia B in the 7MM (2018–2030)
  • Figure 14: Severity- Specific Prevalent Population of Hemophilia B in the 7MM (2018–2030)
  • Figure 15: Prevalent population of Hemophilia B with or without Inhibitors in the 7MM (2018–2030)
  • Figure 16: Treated Prevalent Population of Hemophilia B in the 7MM (2018–2030)
  • Figure 17: Total Diagnosed Prevalent Population of Hemophilia B in the United States (2018–2030)
  • Figure 18: Severity- Specific Prevalent Population of Hemophilia B in the United States (2018–2030)
  • Figure 19: Prevalent population of Hemophilia B with Inhibitors and Without Inhibitors in the United States (2018–2030)
  • Figure 20: Treated Prevalent Population of Hemophilia B in the United States (2018–2030)
  • Figure 21: Total Diagnosed Prevalent Population of Hemophilia B in Germany (2018–2030)
  • Figure 22: Severity- Specific Prevalent Population of Hemophilia B in Germany (2018–2030)
  • Figure 23: Prevalent population of Hemophilia B with or without Inhibitors in Germany (2018–2030)
  • Figure 24: Treated Prevalent Population of Hemophilia B in Germany (2018–2030)
  • Figure 25: Total Diagnosed Prevalent Population of Hemophilia B in France (2018–2030)
  • Figure 26: Severity-Specific Prevalent Population of Hemophilia B in France (2018–2030)
  • Figure 27: Prevalent population of Hemophilia B with or without Inhibitors in France (2018–2030)
  • Figure 28: Treated Prevalent Population of Hemophilia B in France (2018–2030)
  • Figure 29: Total Diagnosed Prevalent Population of Hemophilia B in Italy (2018–2030)
  • Figure 30: Severity- Specific Prevalent Population of Hemophilia B in Italy (2018–2030)
  • Figure 31: Prevalent population of Hemophilia B with or without Inhibitors in Italy (2018–2030)
  • Figure 32: Treated Prevalent Population of Hemophilia B in Italy (2018–2030)
  • Figure 33: Total Diagnosed Prevalent Population of Hemophilia B in Spain (2018–2030)
  • Figure 34: Severity- Specific Prevalent Population of Hemophilia B in Spain (2018–2030)
  • Figure 35: Prevalent population of Hemophilia B with or without Inhibitors in Spain (2018–2030)
  • Figure 36: Treated Prevalent Population of Hemophilia B in Spain (2018–2030)
  • Figure 37: Total Diagnosed Prevalent Population of Hemophilia B in the United Kingdom (2018–2030)
  • Figure 38: Severity-Specific Prevalent Population of Hemophilia B in the United Kingdom (2018–2030)
  • Figure 39: Prevalent population of Hemophilia B with or without Inhibitors in the United Kingdom (2018–2030)
  • Figure 40: Treated Prevalent Population of Hemophilia B in the United Kingdom (2018–2030)
  • Figure 41: Total Diagnosed Prevalent Population of Hemophilia B in Japan (2018–2030)
  • Figure 42: Severity- Specific Prevalent Population of Hemophilia B in Japan (2018–2030)
  • Figure 43: Prevalence of Hemophilia B with Inhibitors and Without Inhibitors in Japan (2018–2030)
  • Figure 44: Treated Prevalent Population of Hemophilia B in Japan (2018–2030)

Related Reports

Hemophilia B - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2020

$ 2000

Hemophilia B - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2020

Hemophilia B - Market Insight, Epidemiology And Market Forecast - 2032

$ 7500

Hemophilia B - Market Insight, Epidemiology And Market Forecast - 2032

Tags:

loader

Request Sample

View Pricing